Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Jazz Pharmaceuticals plc reported revenue of $4.27B, up 4.9% year over year. Operating margin was -10.1% and net margin -8.3%, on a free-cash-flow margin of 30.4% with capital expenditure at 1.4% of revenue. Every figure is computed directly from JAZZ's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4.27B | -10.1% | -8.3% |
| FY2024 | $4.07B | 17.6% | 13.8% |
| FY2023 | $3.83B | 15.1% | 10.8% |
| FY2022 | $3.66B | -1.8% | -6.1% |
| FY2021 | $3.09B | 5.5% | -10.7% |
How does JAZZ compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.